ACT for the Home Management in Malagasy Children

NCT ID: NCT00612547

Last Updated: 2009-02-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-02-29

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the feasibility, the acceptability and the effectiveness of the use of the Artesunate + Amodiaquine Fixed Dose Combination for the home management of presumed malaria in Malagasy children by the community-based service providers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective

To assess the feasibility, the acceptability and the effectiveness of the use of the Artesunate + Amodiaquine Fixed Dose Combination for the home management of presumed malaria in Malagasy children by the community-based service providers

Secondary objectives

To assess the reliability of the use of the malaria rapid diagnostic tests (RDT) by the community-based service providers in the Malagasy home management strategy

To assess the frequency of short-term and long-term side effects of the Artesunate + Amodiaquine Fixed Dose Combination used for the home management of presumed malaria in Malagasy children by the community-based service providers

To assess the real burden of the malaria in children under the age of five years in 2 different epidemiological strata of Madagascar (central highlands and equatorial strata)

Type of study

Follow-up of a cohort of 1200 children under the age of five years during 1 year

Studied population

All children under the age of five years (2 months to 5 years) having fever and consulting the community-based service provider, residing in the zone covered by the community-based service provider throughout the entire follow-up period Investigators Four community-based service providers, four field physicians and two supervisors number of district: 2 (Moramanga and Manakara)

condition: fever intervention: artesunate + amodiaquine phase: phase IV

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fever Suspected Malaria

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Protozoan Infections Communicable Diseases Malaria Infection Malaria, falciparum Malaria, vivax Artesunate Amodiaquine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observation

Children under the age of five years (2 months to 5 years) residing in the zone covered by the community-based service provider throughout the entire follow-up period

Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)

Intervention Type DRUG

Tablet:

Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)

Tablet:

Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All children under the age of five years (2 months to 5 years) having fever and consulting the community-based service provider, residing in the zone covered by the community-based service provider throughout the entire follow-up period, having signed an informed consent

Exclusion Criteria

* Children with no informed consent
Minimum Eligible Age

2 Months

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Population Services International

OTHER

Sponsor Role collaborator

Reggio Terzo Mondo

UNKNOWN

Sponsor Role collaborator

Santé Net

UNKNOWN

Sponsor Role collaborator

Inter Aide Santé,

UNKNOWN

Sponsor Role collaborator

Adventist Development and Relief Agency

OTHER

Sponsor Role collaborator

SAF FJKM

UNKNOWN

Sponsor Role collaborator

Sanofi

INDUSTRY

Sponsor Role collaborator

Institut Pasteur de Madagascar

OTHER

Sponsor Role collaborator

National Malaria Control Programme, Madagascar

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Institut Pasteur de Madagascar

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Benjamin Ramarosandratana, MD

Role: STUDY_CHAIR

National Malaria Control Programme

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Pasteur

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Madagascar France

References

Explore related publications, articles, or registry entries linked to this study.

Ratsimbasoa A, Ravony H, Vonimpaisomihanta JA, Raherinjafy R, Jahevitra M, Rapelanoro R, Rakotomanga Jde D, Malvy D, Millet P, Menard D. Management of uncomplicated malaria in febrile under five-year-old children by community health workers in Madagascar: reliability of malaria rapid diagnostic tests. Malar J. 2012 Mar 25;11:85. doi: 10.1186/1475-2875-11-85.

Reference Type DERIVED
PMID: 22443344 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACTComMada

Identifier Type: -

Identifier Source: org_study_id